荣昌生物制药（烟台）股份有限公司

Home
About Us
RemeGen Co., Ltd. (Yantai) was co-founded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, and Dr. Jianmin Fang a Canadian-American scientist. RemeGen is headquartered in Yantai, Shandong Province, China, with R&D centers and offices in China and the United States.

■Our Company ■Our Vision ■Board of Directors ■Management Team
Products/R&D Pipelines
Telitacicept

The World’s First Innovative Dual-Target Biological Medication to Treat Systemic Lupus Erythematosus

Disitamab Vedotin

The First Independently Developed Novel ADC Drug in China

■Marketed Products ■Marketing Team ■Product Pipeline
Science&Manufacturing
■Innovation Capacity ■Technology Platform ■Manufacturing ■Quality System ■Talent Team
Investors

STAR Market stock code：荣昌生物：688331.SH

【2024.05.07】 Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

HKEX stock code 荣昌生物：09995.HK

【2024.04.26】 [Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

■Financial Reports ■Circulars ■Activities and Presentations

■Investor Events Calendar ■Corporate Governance ■Investor Relation Contact Information
News
- Company News
- Media Reports
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma

BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally adv

■Company News ■Media Reports
Join Us
■Recruitment ■Working at RemeGen ■Compensation and Benefits
Contact Us
■Yantai, China

Address: No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.

Telephone:（+86）535-3573511

■Company Address ■Clinical Trial ■Human Resource ■ Adverse Reactions Reporting

About Us

Home > About Us > Board of Directors > Jian Lin

Jian Lin

Executive Director

Mr. Lin Jian served as the Chairman of the company from July 2008 to June 2019, as a Director from July 2008 to April 2020, and as the Executive Director since May 2020, primarily responsible for the overall management, business, and strategic planning of the company.

Mr. Lin Jian received a Bachelor of Engineering degree in Traditional Chinese Medicine from Heilongjiang Business College (now known as Harbin University of Commerce) in 1982. He has over 35 years of experience in the pharmaceutical industry.